Skip to main content

Select Drug Profiles

Practice Management

Revealed Opportunism: How Physicians “Game” Prior Authorization Protocols Until They Are Rescinded

Natan R. Kahan, RPh, MHA, PhD, Dan-Andrei Waitman, MD, MPH, David P. Chinitz, PhD

Stakeholder Perspective

A Matter of Trust

by Albert Tzeel, MD, MHSA, CPE, FAAPL

Original Research

Treatment of Chronic Hepatitis C Infection with Sofosbuvir-Based Regimens in a Commercially Insured Patient Population

John Barron, PharmD, Yiqiong Xie, PhD, Sze-jung Wu, PhD, Jeff White, PharmD, Joseph R. Singer, MD, Bernard Tulsi, MSc, Alan Rosenberg, MD

Stakeholder Perspective

Evaluating the True Value of High-Cost Therapies for Hepatitis C Infection

by Jack E. Fincham, PhD, RPh

Original Research

Evaluating Outcomes in Patients with Overactive Bladder within an Integrated Healthcare Delivery System Using a Treatment Patterns Analyzer

Daniel B. Ng, PharmD, MBA, Melissa McCart, PharmD, MS, Christopher Klein, BS, Chelsey Campbell, PharmD, MBA, Robert Schoenhaus, PharmD, Todd Berner, MD

Stakeholder Perspective

Implications of Big Data Analysis in the Real-World Setting: The Case of Overactive Bladder Treatment

by Kelly Huang, PhD

Practice Management

Employer Perspectives on a Specialty Drug Step-Therapy Program Evaluation

Matthew Harman, PharmD, MPH, F. Randy Vogenberg, PhD, FASHP

The Challenge of Balancing Access to and Paying for New, High-Cost Cancer Therapies

James T. Kenney, RPh, MBA

Leukemia, Oncology

Refining the Use of CAR T-Cells in Patients with Acute Lymphoblastic Leukemia

Leukemia, Oncology

CAR T-Cell Therapy Produces High Response Rates in Refractory B-Cell Malignancies

Breast Cancer, Oncology

Extending Letrozole Therapy Beyond 5 Years in Early Breast Cancer Reduces Recurrence

Multiple Myeloma, Oncology

Three-Drug Regimen with Daratumumab a New Standard of Care for Relapsed or Refractory Multiple Myeloma

Atezolizumab Could Be Start of “Seismic Shift” in Metastatic Bladder Cancer Therapy

Page 106 of 244
Results 1051 - 1060 of 2438